Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,463 total articles

Beeline Expects Q3 2026 Revenue to Reach Highest Level Since 2021, Record Margins, Lower Net Loss and Lowest Adjusted EBITDA Loss in 5 Years

Beeline Expects Q3 2026 Revenue to Reach Highest Level Since 2021, Record Margins, Lower Net Loss and Lowest Adjusted EBITDA Loss in 5 Years

Beeline Holdings announces strong preliminary Q3 2026 financial results with highest revenue since 2021, record margins, reduced net loss, and improved adjusted EBITDA loss. The company attributes growth to strategic shift towards Non-QM lending and introduces a new Home Equity Investment product to diversify offerings beyond traditional mortgage m…

Zenas BioPharma to Host Virtual R&D Event

Zenas BioPharma to Host Virtual R&D Event

Zenas BioPharma, a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, plans to host a virtual R&D event on October 27, 2026. The event will feature updates on their pipeline products including obexelimab and ZB021, with expert insights on the clinical landscape. The company is advancing two late-stage molecule…

ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

ProMIS Neurosciences has appointed Ivana Rubino, Ph.D., a seasoned executive with extensive experience at Biogen and Roche, as Chief Commercial Officer. This move strengthens ProMIS' commercial and development leadership as the company progresses with its Alzheimer's disease antibody therapy PMN310, moving toward expected 12-month topline data in Q…

Why Do You Keep Gaining Weight Back After Losing It

Why Do You Keep Gaining Weight Back After Losing It

Medifast, Inc. (NYSE: MED) highlights the challenges of weight regain after weight loss and introduces its Trilivy™ metabolic health system designed to address key drivers of weight regain. Trilivy targets metabolic dysfunction by preserving lean mass, reducing visceral fat, and developing long-term healthy habits through coaching and behavioral sc…

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

Regeneron Pharmaceuticals announced multiple presentations at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting advances across several cancers including cutaneous squamous cell carcinoma, non-small cell lung cancer, ovarian cancer, melanoma, and cancer-associated thrombosis. Key data include Phase 3 survival outcomes for …

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

Kamada Ltd., a biopharmaceutical company listed on NASDAQ and the Tel Aviv Stock Exchange, announced the launch of two new biosimilar products in Israel: Ustekinumab-Kamada and Enoxaparin-Kamada. These launches expand its biosimilar portfolio, which currently includes two other products. Kamada expects biosimilar sales to grow from $4 million in 20…

Simply Good Foods to Report Fourth Quarter Fiscal Year 2026 Financial Results on Tuesday, October 27, 2026

Simply Good Foods to Report Fourth Quarter Fiscal Year 2026 Financial Results on Tuesday, October 27, 2026

The Simply Good Foods Company, traded on NASDAQ as SMPL, announced it will release its fourth quarter fiscal year 2026 financial results on October 27, 2026. The announcement includes details of a live conference call featuring senior executives and provides information for investor participation. The company is recognized as a leader in nutritiona…

Auddia Cancels October 7th Shareholder Meeting to Align Merger Vote with Expanding AI Infrastructure Opportunity

Auddia Cancels October 7th Shareholder Meeting to Align Merger Vote with Expanding AI Infrastructure Opportunity

Auddia Inc. has canceled its October 7 shareholder meeting originally scheduled to approve a merger with Thramann Holdings due to insufficient votes from shareholders on the original record date. The company cites significant growth in the strategic value of LT350, a Thramann subsidiary deploying innovative distributed AI datacenter infrastructure,…

SNDL Announces Resignation of Director

SNDL Announces Resignation of Director

SNDL Inc., a major Canadian cannabis and liquor retailer listed on NASDAQ and CSE, announced the immediate resignation of its board director Carlo Cannell. The company expressed gratitude for his contributions. This leadership change occurs without additional operational updates.

MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics

MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics

MapLight Therapeutics celebrates co-founder Dr. Karl Deisseroth's receipt of the 2026 Nobel Prize in Physiology or Medicine for the development of optogenetics, a foundational technology that inspired the company’s circuit-based drug discovery approach. MapLight utilizes optogenetics to identify neural circuits linked to CNS disorders and develop t…

OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain

OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain

OKYO Pharma has initiated patient enrollment in the Phase 3 NEPTUNE clinical trial evaluating urcosimod, a novel investigational treatment for neuropathic corneal pain (NCP), a severe and debilitating ocular condition with no FDA-approved therapies. The multicenter registrational study is underway across multiple US and European sites aiming to est…

Xanadu and GlobalFoundries Announce Strategic Partnership to Accelerate Utility-Scale Quantum Manufacturing

Xanadu and GlobalFoundries Announce Strategic Partnership to Accelerate Utility-Scale Quantum Manufacturing

Xanadu Quantum Technologies announced a strategic multi-year partnership with GlobalFoundries to industrialize and scale the production of advanced photonic components essential for utility-scale quantum computing. Leveraging GlobalFoundries' 300 mm manufacturing line in Malta, NY, the collaboration focuses on deploying Xanadu's ultra-low loss sili…

Bullish releases September 2026 monthly metrics

Bullish releases September 2026 monthly metrics

Bullish, a US-listed global digital asset platform, released its September 2026 monthly metrics covering spot and derivatives trading volume, average trading spreads, and volatility for key cryptocurrencies Bitcoin and Ethereum. The company provides institutionally focused regulated market infrastructure and information services, including its exch…

Bimergen Energy Co-CEO Joins Featured Keynote Panel at MoneyShow; Highlights 2026 Milestones in Company Presentations

Bimergen Energy Co-CEO Joins Featured Keynote Panel at MoneyShow; Highlights 2026 Milestones in Company Presentations

Bimergen Energy, a U.S.-based renewable energy infrastructure developer focused on battery energy storage systems, reported its first-ever revenue and GAAP profitability in Q2 2026. The company achieved $7.9 million in revenue with a net income of $1.6 million. It also completed a $13.6 million public offering and uplisted to the NYSE American, str…

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

Telix Pharmaceuticals has commenced the first U.S. commercial doses of Pixclara® (floretyrosine F 18), the only FDA-approved radiopharmaceutical PET imaging drug for glioma. The drug aids differentiation of recurrent or progressive glioma from treatment-related changes in adult and pediatric patients, addressing a significant unmet medical need. Ma…